Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arrowhead Pharmaceuticals (ARWR) EBITDA Margin (2016 - 2025)

Arrowhead Pharmaceuticals' EBITDA Margin history spans 16 years, with the latest figure at 10.79% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 704403.0% year-over-year to 10.79%; the TTM value through Dec 2025 reached 21.64%, up 2578736.0%, while the annual FY2025 figure was 3.83%, 1694895.0% up from the prior year.
  • EBITDA Margin reached 10.79% in Q4 2025 per ARWR's latest filing, up from 6.71% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 67.83% in Q1 2025 to a low of 7033.24% in Q4 2024.
  • Average EBITDA Margin over 5 years is 808.98%, with a median of 165.88% recorded in 2021.
  • Peak YoY movement for EBITDA Margin: tumbled -368990bps in 2023, then skyrocketed 704403bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 229.28% in 2021, then soared by 71bps to 67.04% in 2022, then tumbled by -5504bps to 3756.94% in 2023, then plummeted by -87bps to 7033.24% in 2024, then skyrocketed by 100bps to 10.79% in 2025.
  • Per Business Quant, the three most recent readings for ARWR's EBITDA Margin are 10.79% (Q4 2025), 6.71% (Q3 2025), and 639.91% (Q2 2025).